Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-BCGvacc
2024-514428-18-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2025
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bcg vaccine and Rabies vaccine in Tuberculosis (TB) and rabies, sponsored by Leiden University Medical Center. Primary endpoint: Induction of mycobacterial growth control measured by MGIA. Planned start Jul 2025; status: authorised.
02
Drugs
bcg vaccineRabies vaccine
03
Conditions
Tuberculosis (TB)rabies
Beyond the preview
Go deeper on 2024-514428-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514428-18-00.